

University of Groningen

## The biology of human hematopoietic stem and progenitor cells in acute myeloid leukemia, aging and autologous transplantation

Woolthuis, Carolien Marthe

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2013

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Woolthuis, C. M. (2013). *The biology of human hematopoietic stem and progenitor cells in acute myeloid leukemia, aging and autologous transplantation*. s.n.

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

# CHAPTER 1

## General introduction

## The hematopoietic system

### *General introduction to the hematopoietic system*


The adult bone marrow is capable of replenishing all mature blood cell types during the complete lifespan of an individual and is therefore a unique and intriguing tissue. Because of the short life span of most mature blood cells, the hematopoietic cell production is an ever ongoing process with an estimated output of 1.5 million blood cells every second.<sup>1,2</sup> The hematopoietic system, responsible for this process, is considered a hierarchical system with hematopoietic stem cells (HSCs) on top of the hierarchy. The experimental concept of HSCs can be traced back to the early fifties of the last century, when it was observed that the injection of spleen or bone marrow cells could prevent mice from the lethal effects of irradiation-induced bone marrow failure.<sup>3,4</sup> In 1961 Till and McCulloch reported their breakthrough experiments indicating the existence of cells in the marrow that could give rise to mixed myeloerythroid progeny and the ability of some of these cells to make more of themselves, i.e. to self-renew.<sup>5</sup> Since these first experiments that suggested the presence of multipotent HSCs, the field of HSC research has made major progress in identifying, characterizing and isolating HSCs and new insights in HSC biology are reported frequently.

### *The hematopoietic hierarchy*

HSCs are defined as single cells with the lifelong ability to self-renew as well as to generate progeny that can differentiate in order to produce all blood cell lineages.<sup>6,7</sup> It is becoming more and more clear, at least for the mouse system, that HSCs can be subdivided into long-term HSCs (LT-HSCs) and short-term HSCs (ST-HSCs).<sup>6,8</sup> LT-HSCs are considered the slowest cycling HSCs and in a steady state adult hematopoietic system they reside in a quiescent cell cycle state. Maintenance of quiescence is crucial for HSC preservation and ensures the lifelong replenishment of mature blood cells.<sup>9-11</sup> ST-HSCs are as multipotent as LT-HSCs and are predominantly quiescent in steady-state conditions, but will cycle rarely yet consistently in order to maintain hematopoiesis and will be triggered more easily by injury or loss when enhanced blood cell production is needed. Being active contributors to steady-state hematopoiesis, ST-HSCs will ultimately exhaust and be replenished by LT-HSCs. Recent studies have shown that within the HSC compartment different cell subtypes can be distinguished. Based on a measurement of the predominant lineages within their total output HSC subsets were characterized as myeloid-biased, lymphoid-biased or balanced.<sup>12,13</sup> Other studies distinguished HSC subtypes as lymphoid-deficient ( $\alpha$ ), balanced ( $\beta$ ), or myeloid-deficient ( $\gamma$  and  $\delta$ ). Both  $\alpha$  and  $\beta$  HSCs are found to contribute similarly to the circulating pool of myeloid cells.<sup>14</sup> Serial transplantation experiments have shown that only  $\alpha$  and  $\beta$  HSCs can be serially transplanted, and their unique differentiation behaviors are usually maintained over periods of years in primary transplant recipients.<sup>14,15</sup> In addition, by using a genetic model in which a tetracycline responsive fusion protein histone 2B green fluorescent protein (H2B-GFP) was used to pulse label hematopoietic

stem and progenitor cells, evidence was provided for the existence of two HSC populations with distinct division kinetics, namely a dormant subset and a more activated population.<sup>16</sup>

Following the branches of the hematopoietic tree, the immediate progeny of HSCs are multipotent progenitors (MPPs) that retain full lineage potential but have a very limited self-renewal capacity and are mainly cycling.<sup>17</sup> MPPs are followed in hierarchy by committed progenitors which are simply named after their lineage commitment, i.e. the common lymphoid progenitor (CLP) and the common myeloid progenitor (CMP).<sup>18;19</sup> The latter will further differentiate in the megakaryocyte erythrocyte progenitor (MEP) and granulocyte macrophage progenitor (GMP).<sup>18;20;21</sup> At the end of the hierarchy, the mature effector blood components are preceded by their lineage restricted precursors (Figure 1). Of note, recent studies conducted in the murine system suggest that MPPs initially differentiate into lymphoid-primed multipotent progenitors (LMPPs) with lymphoid and granulocyte macrophage but no megakaryocyte erythrocyte potential and a separate MEP population.<sup>22-25</sup>



**Figure 1 Schematic representation of the hematopoietic hierarchy**

Abbreviations: LT-HSC: long-term hematopoietic stem cell, ST-HSC: short-term hematopoietic stem cell, MPP: multipotent progenitor, LMPP: lymphoid-primed multipotent progenitor, MkEP: early megakaryocyte erythrocyte progenitor, CMP: common myeloid progenitor, CLP: common lymphoid progenitor, GMP: granulocyte macrophage progenitor, and MEP: megakaryocyte erythrocyte progenitor.

*Identification of distinct hematopoietic populations by cell surface markers*

Since studies in the human hematopoietic system are hampered by both ethical and experimental issues, most of our knowledge comes from the murine system. Although major progress has been made, the identification of the human counterparts of the murine hematopoietic stem and progenitor cells is still lagging behind and is subject to continuing discussion and investigation.<sup>26</sup> Already early on in the search for human HSCs, the cell surface protein CD34 was identified as an important marker for immature hematopoietic cells. CD34-enriched populations were demonstrated to be able to form colonies *in vitro* and reconstitute the hematopoietic system upon *in vivo* transplantation.<sup>27-30</sup> With the development of severe immunocompromised mice (NOD-SCID and SCID-humanized mice) a murine model became available for the analysis of human HSCs, making further characterization and purification possible.<sup>31,32</sup> To date, human HSCs are thought to reside in the Lin-CD34<sup>+</sup>CD38<sup>-</sup>CD90<sup>+</sup>CD45RA<sup>-</sup> compartment, which give rise to Lin-CD34<sup>+</sup>CD38<sup>-</sup>CD90<sup>+</sup>CD45RA<sup>-</sup> MPPs.<sup>33,34</sup> However, the complexity of the human HSC compartment and its identification was evidenced by the demonstration of multipotent SCID repopulating cells negative for CD34 expression.<sup>35</sup> Moreover, recent studies identified CD49f (ITGA6) as a specific HSC marker in human cord blood.<sup>36</sup> In the same study HSCs negative for CD90 expression were identified. Human hematopoietic progenitors have also been characterized. The more committed Lin-CD34<sup>+</sup>CD38<sup>+</sup> can be separated into the myeloid branched CMP, GMP and MEP based on differential expression of CD123 (IL3RA), CD110 and CD45RA.<sup>37,38</sup> Less straight-forward is the characterization of the human CLP. Whereas marker definitions of the myeloid progenitors are consistent in bone marrow and cord blood, different marker expression profiles were shown for lymphoid progenitors. For bone marrow a Lin-CD34<sup>+</sup>CD38<sup>+</sup>CD10<sup>+</sup>CD45RA<sup>+</sup> CLP was identified,<sup>39</sup> while the human cord blood CLP was characterized as CD34<sup>+</sup>CD38<sup>-</sup>CD7<sup>+</sup>, a population not existing in adult bone marrow.<sup>40,41</sup> To add to the complexity, the CD10 expression of the bone marrow CLP is still debated and an IL7RA expressing bone marrow CLP has been suggested.<sup>7</sup> In general, the transition and lineage restriction steps between early CD34<sup>+</sup>CD38<sup>-</sup> human HSCs, MPPs and their more committed CD34<sup>+</sup>CD38<sup>+</sup> progeny are poorly defined and a human LMPP population has not yet been identified.

*The hematopoietic stem cell niche*

HSCs do not function alone, but are highly dependent on signals from surrounding cells that are found within a specialized micro-environment within the bone marrow. This micro-environment is termed the HSC niche. For a long time, niches were a theoretical concept strongly supported by the observation that transplanted HSCs survive and grow only in particular tissue conditions. In recent years progress has been made in our understanding of cellular components that comprise the niche and mechanisms that underlie the interaction between hematopoietic stem and progenitor cells and their niche.<sup>42-44</sup> The HSC niche is thought to consist of osteolineage cells, sinusoidal endothelial cells, mesenchymal stromal and stem cells, sympathetic neurons, and the extracellular matrix. HSCs were

originally detected in the endosteal regions of the bone marrow<sup>42,45</sup> and recent findings have suggested the existence of distinct perivascular niches.<sup>46-49</sup> Most probably, both endosteal and vascular or perivascular niches contribute to HSC function. Continuing experiments will further expand our knowledge of HSC niches and their relevance in the hematopoietic system. Moreover, a potential role for the niche in disease pathogenesis is an intriguing concept that deserves further research.

## **Malignant hematopoiesis and acute myeloid leukemia**

### *Malignant hematopoiesis*

To ensure adequate blood cell production, the hematopoietic system is strictly regulated by both cell intrinsic as well as extrinsic factors.<sup>50-53</sup> As with cancers of other tissues, malignant hematopoietic disorders are characterized by a disturbance of the normal hematopoietic biology and of these disorders leukemia is probably one of the most dramatic examples. In general, leukemia can be characterized by uncontrolled proliferation and a block in maturation. Immature hematopoietic cells, also known as blasts, lose the ability to differentiate normally and to respond to normal cell regulating mechanisms. The leukemic blasts can find their origin at any early stage in the hematopoietic hierarchy. Leukemia can be subdivided both clinically and pathologically in four major categories combining two broad classifications. One classification stratifies leukemias according to lineage into either myeloid or lymphoid.<sup>54;55</sup> The other classification tends to indicate the level of disease progression and distinguishes acute from chronic leukemia. This thesis focuses on acute myeloid leukemia, which will be discussed in further detail.

### *Acute myeloid leukemia*

Acute myeloid leukemia (AML) is characterized by an increase in the number of myeloid cells in the marrow and an arrest in their maturation. The condition is frequently resulting in hematopoietic insufficiency, i.e. granulocytopenia, thrombocytopenia and anemia, and can present with or without leukocytosis.<sup>54;56</sup> Most of the clinical symptoms can be directly related to the pancytopenia and patients typically present with fatigue, abnormal bleeding, frequent and unusual infections and fever. AML progresses rapidly and is typically fatal within months or even weeks if left untreated.

**Table 1** French-American-British classification of acute myeloid leukemia

Type	Name
M0	Myeloid leukemia with minimal differentiation
M1	Myeloid leukemia without maturation
M2	Myeloid leukemia with maturation
M3	Promyelocytic leukemia
M4	Myelomonocytic leukemia
M4eo	Myelomonocytic leukemia with abnormal eosinophils
M5	Monocytic leukemia
M6	Erythroid leukemia
M7	Megakaryocytic leukemia

*Classification of acute myeloid leukemias*

AML is a very heterogeneous disease, both clinically as well as biologically.<sup>54;56</sup> For decades, the French-American-British (FAB) classification was used to classify AML according to the morphological appearance of the blasts and their immunohistochemical features (Table 1).<sup>57</sup> However, with the discovery of a number of recurring genetic alterations that could be associated with defects in maturation and proliferation in AML subtypes, the traditional FAB classification became less adequate. Importantly, the discovered genetic abnormalities could predict clinical behavior and outcome better than morphology alone. In 2001 a more clinically useful classification system was launched by the World Health Organization (WHO). The WHO classification attempts to incorporate those disease characteristics that have proved to have clinical and biologic relevance into a useful, working nomenclature.<sup>58</sup> Inherent to this ambition is the necessitation to revise the classification based on new findings in the rapidly evolving scientific field of AML. Indeed, recently a revised WHO classification was published incorporating newly identified prognostic factors.<sup>59</sup> For the first time, AML subgroups with a specific gene mutation have been included as provisional entities, i.e. AML with a mutation in CCAAT/enhancer binding protein alpha (CEBPA) and AML with mutated nucleophosmin 1 (NPM1). Table 2 summarizes the latest WHO classification for AML (2008).

**Table 2** WHO classification of acute myeloid leukemia and related neoplasms**Acute myeloid leukemia with recurrent genetic abnormalities**

AML with t(8;21)(q22;q22); RUNX1-RUNX1T1  
 AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFβ-MYH11  
 APL with t(15;17)(q22;q12); PML-RARA  
 AML with t(9;11)(p22;q23); MLLT3-MLL  
 AML with t(6;9)(p23;q34); DEK-NUP214  
 AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1  
 AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1  
 Provisional entity: AML with mutated NPM1  
 Provisional entity: AML with mutated CEBPA

**Acute myeloid leukemia with myelodysplasia-related changes****Therapy-related myeloid neoplasms****Acute myeloid leukemia, not otherwise specified**

AML with minimal differentiation  
 AML without maturation  
 AML with maturation  
 Acute myelomonocytic leukemia  
 Acute monoblastic/monocytic leukemia  
 Acute erythroid leukemia  
     Pure erythroid leukemia  
     Erythroleukemia, erythroid/myeloid  
 Acute megakaryoblastic leukemia  
 Acute basophilic leukemia  
 Acute panmyelosis with myelofibrosis

**Myeloid sarcoma****Myeloid proliferations related to Down syndrome**

Transient abnormal myelopoiesis  
 Myeloid leukemia associated with Down syndrome

**Blastic plasmacytoid dendritic cell neoplasm**



*Prognostic factors in acute myeloid leukemia*

Clinical heterogeneity in AML implies the need for prognostic markers that could help doctors and their patients choose the best suitable therapy. While highly toxic therapies including allogeneic stem cell transplantation might be the only chance of survival for patients diagnosed with a poor prognostic AML subtype, therapy related morbidity and mortality risks should not outweigh disease related mortality risk in good prognostic patients. An accumulating number of studies have shown that karyotype and mutation status of certain genes provide important prognostic information. Among the disease related prognostic factors, pre-treatment cytogenetics remain the most important and patients can be divided in three major prognostic categories based on their karyotype. Patients with acute promyelocytic leukemia (APL) with the t(15;17)(q22;q12-21) and those with the core binding factor (CBF) leukemias with t(8;21)(q22;q22) or inv(16)(p13;q22)/t(16;16)(p13;q22) are characterized by a relative favorable prognosis and form the favorable risk group.<sup>60-63</sup> In contrast, patients diagnosed with abnormalities of 3q, deletions of 5q or 7q, monosomies of chromosome 5 and/or 7, abnormalities of 11q23, t(6;9), t(9;22) or a complex karyotype (i.e. three or more unrelated chromosomal abnormalities) have a poor prognosis.<sup>60-62</sup> An important recent observation is the existence of a subgroup of patients within the poor risk group with an extremely poor outcome, characterized by the presence of an autosomal monosomy in conjunction with at least one other autosomal monosomy or structural abnormality (monosomal karyotype).<sup>64</sup> The intermediate risk group includes all patients with a normal karyotype AML and those who do not fit in the favorable or poor prognostic categories. The intermediate risk subgroup represents the largest (approximately 45%) and most heterogeneous group of patients. In the last decades, there have been great efforts in identifying molecular abnormalities that have significant prognostic impact and can help further classify patients in the intermediate risk group. The most prognostically important and prevalent gene mutations in AML will be discussed briefly. Mutations in FMS-like tyrosine kinase 3 (FLT3) are among the most common genetic changes in AML.<sup>65</sup> FLT3 is a member of the class III receptor tyrosine kinase family and plays a role in proliferation, survival and differentiation of hematopoietic progenitor cells. Mutations in FLT3 come in two forms of which the most common are internal tandem duplications (ITD). Less frequently mutations affect the tyrosine kinase domain (TKD). Several studies have shown that prognosis of AML with FLT3-ITD is significantly worse compared with AML without the mutation, but the allelic burden seems of importance.<sup>66-69</sup> The prognostic relevance of the FLT3-TKD mutation has remained controversial.<sup>70;71</sup> Mutation of NPM1 is the most frequently found molecular abnormality in AML. The presence of an NPM1 mutation has major prognostic implications, especially in the absence of FLT3-ITD. Part of this thesis focuses on NPM1 mutated AML and this topic will therefore be discussed in more detail in the next paragraph. Like NPM1-mutated AML, AML with a mutation in CEBPA has been included as a provisional entity in the WHO classification system. CEBPA encodes for CCAAT/enhancer binding protein  $\alpha$ , a granulocytic differentiation factor important in the regulation of myeloid progenitors.<sup>72;73</sup> CEBPA mutations are particularly frequent in

normal karyotype AML.<sup>74</sup> Importantly, CEBPA mutations can be divided in two subgroups, namely mono-allelic and bi-allelic mutations with distinct impact on prognosis, presence of concurring gene mutations and gene expression.<sup>75,76</sup> Currently, only CEBPA bi-allelic mutations are associated with favorable outcome and as a consequence, not all CEBPA mutated AML but only AML with a CEBPA bi-allelic mutation should be considered a distinct prognostic category.<sup>77</sup> With the application of whole genome sequencing technologies, a number of novel gene mutations have been discovered. Mutations in the isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) genes have been identified as recurrent molecular abnormalities in AML and result in a substrate shift to  $\alpha$ -ketoglurate ( $\alpha$ -KG) with accumulation of 2-hydroxyglutarate (2-HG) that is a putative oncogenic metabolite.<sup>78-80</sup> Recently it was suggested that 2-HG can lead to DNA methylation alterations.<sup>81</sup> IDH1 mutations were reported to be an adverse prognostic factor in cytogenetically normal AML, although their prognostic impact in molecular subgroups based on NPM1, FLT3 and CEBPA mutations has been controversial.<sup>78,79,82,83</sup> The prognostic significance of IDH2 mutations is also still under discussion. Mutations in DNMT3A, encoding for a methyltransferase catalyzing the addition of a methyl group to the cytosine residue of CpG dinucleotides, were also discovered by next-generation sequencing techniques.<sup>84,85</sup> Their presence has been associated with an unfavorable prognosis.<sup>86</sup> Recently, mutations in the TET oncogene family member 2 (TET2) were observed in patients with AML and in other myeloid disorders.<sup>87</sup> TET2 was identified as a candidate tumor suppressor gene and the TET2 proteins are involved in epigenetic regulation. Like with the other novel gene mutations, the prognostic impact of TET2 mutations is still under debate.

To summarize, the prognostic classification of normal karyotype AML patients is rapidly progressing. Discoveries of disease related prognostic markers have led to new disease entities and revision of traditional classification systems within a decade. Testing for FLT3, NPM1 and CEBPA is now common in clinical practice and influences treatment decisions. Nonetheless, newly identified prognostic markers need to be carefully examined in independent and large cohorts of patients in order to evaluate their value as an independent prognostic factor.

## **Nucleophosmin in acute myeloid leukemia**

### *Nucleophosmin as a multifunctional protein*

Nucleophosmin is a highly expressed multifunctional phosphoprotein that mainly resides in the nucleoli of the cell. The gene encoding for this protein (NPM1) is mapping to chromosome 5q35 and contains twelve exons. Nucleophosmin is a member of the nucleoplasmin family of proteins and acts as a nuclear chaperone protein. Various functional domains are identified through which nucleophosmin can bind to many partner proteins, thereby participating in important cellular processes. Nucleophosmin is mainly localized in the nucleoli, but it can shuttle between the nucleus and cytoplasm. This shuttling activity plays an important role in ribosome biogenesis, since

nucleophosmin takes part in the transport of pre-ribosomal particles.<sup>88</sup> In addition to a nuclear localization signal (NLS), nucleophosmin also has a nuclear export signal (NES). With this NES nucleophosmin can provide the necessary export signal required to transport components of the ribosome to the cytosol. By direct interaction with the ribosomal L5 protein (rpL5), an integral component of the 60S ribosomal subunit containing 5S rRNA, nucleophosmin contributes to the nuclear export of rpL5-5S rRNA complexes. In the cytoplasm nucleophosmin was shown to be present in the ribosomal subunits 40S, 60S, 80S, and polysomes, implying a role in the ribosome maturation in the cytosol and also in the process of translation.<sup>89</sup> Involvement of nucleophosmin in the apoptotic response to stress and oncogenic stimuli is revealed by its ability to modulate ARF and p53. Nucleophosmin associates with ARF in the nucleolus and stabilizes ARF by retarding its turnover.<sup>90</sup> Since NPM has a role in ribosome transport, it has been suggested that NPM facilitates the interaction between ARF and the ribosomal machinery. Besides its activity in ARF pathways, nucleophosmin has also been shown to interact directly with the tumor suppressor p53 and increase its stability and transcriptional activation.<sup>91</sup> Although more research is needed to reveal the precise interaction between NPM and ARF, and NPM and p53, it seems that nucleophosmin plays an important role in modulating ARF and p53 and thereby regulating the oncogenic stress response.<sup>88,92</sup> Further contributing to the idea of nucleophosmin as an important protein in the balance between normal function and possible oncogenic transformation is its role in the maintenance of genomic stability. Functional studies show that nucleophosmin can act as a substrate of Ran-Crm1, a complex involved in regulating centrosome duplication.<sup>93</sup> For the role of nucleophosmin in centrosome duplication a model has been suggested in which nucleophosmin is located in the nucleolus during cell progression from S to G2 phase. Then, at the beginning of mitosis, the nucleolar membrane breaks down and nucleophosmin is thought to associate with the mitotic centrosomes, thereby ensuring the coordination of centrosome and DNA duplication, and restricting centrosome duplication to occur once within a cell cycle.<sup>93,94</sup> In addition to the above described functions of nucleophosmin, research in *Npm1* knockout and *Npm1* heterozygous mice demonstrated an essential role of nucleophosmin in embryonic development. Embryos of *Npm1* knockout mice show deficient anterior brain organogenesis. Interestingly, these embryos show distinct defects in primitive hematopoiesis and die at mid-gestational age. Inactivation of the *Npm1* gene leads to unrestricted centrosome duplication and genomic instability.<sup>95</sup> In summary, the diversity of cellular activities makes nucleophosmin a potential tumor suppressor protein. However, by alternating the NPM1 gene or disturbing the important influencing factors it can become an oncogenic factor.<sup>88,95</sup> The NPM1 gene can therefore function both as an oncogene and as a tumor suppressor, depending on gene dosage, expression levels, interacting partners and cellular localization.

*NPM1 mutations in acute myeloid leukemia*

In 2005 Falini and his colleagues discovered that approximately one third of all cases of AML harbor a heterozygous mutation in the NPM1 gene, leading to aberrant cytoplasmic localization of nucleophosmin in the leukemic blasts.<sup>96</sup> In normal karyotype AML the incidence of NPM1 mutations is even higher and with a frequency of approximately 60% in this subgroup, NPM1 mutations are the most frequently found mutations in AML.<sup>96-100</sup> Currently up to 50 different mutations in the NPM1 gene have been identified.<sup>101;102</sup> The great majority of these mutations involve exon 12, although rare mutations in exon 9 and 11 have been identified.<sup>103-105</sup> All NPM1 mutations result in a shift of the reading frame leading to common changes at the very end of the NPM1 protein C-terminus. The changes induced by the mutation lead to the generation of a new NES which reinforces the Crm1-dependent nuclear export of nucleophosmin protein and loss of tryptophan residues 288 and 290 (or residue 290 alone) which cause the three-helix structure of the nucleophosmin C-terminal domain to unfold, thus preventing or decreasing binding to the nucleolus.<sup>106</sup> The aberrant cytoplasmic localization of nucleophosmin in immunohistochemical stainings led to the discovery of the mutation and is still used for diagnostic purposes. Indeed, immunohistochemistry was described to be fully predictive for the detection of NPM1 mutations in AML and as a consequence NPM1 mutated AML is often indicated by the term NPMc<sup>+</sup> AML.<sup>96;107-109</sup> However, there has been controversy about the sensitivity of immunohistochemistry for the detection of NPM1 mutations.<sup>110</sup> This will be further discussed in Chapter 4 of this thesis.

NPM1-mutated AML has been recognized as a provisional entity in the WHO classification of AML. Indeed, distinct biological and clinical features can be observed in NPM1-mutated AML. Presenting clinical features associated with NPM1 mutated AML are the predominance of female sex and a high bone marrow blast percentage and peripheral blood white blood cell count.<sup>96;101</sup> NPM1-mutated AML typically presents with high CD33 but very low CD34 expression and multilineage involvement is often observed.<sup>96;111;112</sup> Moreover, a specific gene expression signature, characterized by high expression of several HOX genes, and distinct microRNA profile were observed.<sup>100;113;114</sup> NPM1 mutations have been shown to be associated with FLT3-ITD and more recently also with IDH and DNMT3A mutations.<sup>78;79;83;84;86</sup> The prognostic value of NPM1 mutations has been well recognized. The presence of an NPM1 mutation is associated with a good response to induction chemotherapy.<sup>96;98;99</sup> Several studies in normal karyotype AML have consistently shown a favorable prognosis for patients with an NPM1 mutation in the absence of a FLT3-ITD.<sup>98-100;115;116</sup> In patients younger than 60 years, outcome is even similar to those patients with CBF leukemias.<sup>116</sup> After conventional induction and consolidation chemotherapy, younger adult patients with mutated NPM1 without FLT3-ITD have an overall five year survival probability of approximately 60%. Recently it was shown that the favorable prognostic impact of NPM1 mutations also applies to older patients.<sup>117-120</sup>

## **Leukemic stem cells**

### *The leukemic stem cell concept*


Of all AML patients that are eligible for intensive treatment, the great majority achieves complete remission upon induction therapy. In approximately 70-80% of all patients under 60 years of age, conventional chemotherapy will initially result in normal bone marrow morphology, undetectable levels of cytogenetic abnormalities and bone marrow blast counts of less than 5%.<sup>119;121;122</sup> However, the disease typically relapses within months or years after initial diagnosis and overall survival rates do not exceed 40% at five year. It has therefore been postulated that, although current treatment regimens might be capable of eliminating the tumor burden, there must be a rare subset of malignant cells that are not effectively eliminated. Indeed, as is true for the normal hematopoietic system, it has been recognized that AML comprises of a heterogeneous group of cells with distinct differentiation status and proliferation potential.<sup>123;124</sup> These observations have ultimately led to the current model in which AML is organized as a hierarchical system with the so called leukemic stem cells (LSCs) on top of the leukemic hierarchy. LSCs share characteristics with normal hematopoietic stem cells and are defined by their ability to proliferate and renew themselves *in vivo* while at the same time generating clonogenic and more differentiated leukemic progeny. Historically characterized by their capability of transferring leukemia to severe combined immunodeficient (SCID) mice, the terms SCID leukemia-initiating cell (SL-IC) or simply leukemia-initiating cell (LIC) are also often used as synonyms for LSC. The initial evidence for the hierarchy model in AML was provided by landmark studies of the John Dick laboratory.<sup>125;126</sup> Since then, the LSC concept in AML has been subject to intensive investigation and will also be further discussed in this thesis.

## **Acute myeloid leukemia and hematopoietic aging**

### *Acute myeloid leukemia at older age*

AML can present at all ages, but is mainly a disease of the elderly. The incidence of AML increases steeply with age (Figure 2) and approximately 75% of all patients is aged 60 years or more.<sup>127;128</sup> The prognosis of patients with AML is generally considered poor, but is worse in elderly patients. Approximately 70-80% of patients younger than 60 years of age will achieve complete remission<sup>121;122</sup> and overall survival rates are 40-45% at five years after diagnosis. Among patients aged above 60 years with a good performance status complete remission will be achieved in 40-50%. However, cure rates in these elderly patients are less than 10% and median survival time is less than one year.<sup>119;128</sup> Prognosis for older patients with unfavorable cytogenetics or poor performance status is even worse. Cure rates for elderly AML patients have not significantly improved with improvements in supportive care and poor prognosis of these patients can only be partly related to diminished performance status or co-morbidity in older individuals. Other important factors should therefore be involved. Indeed,

several observations strongly suggest that the biological nature of AML changes as the age of the patient increases. Compared to AML in younger patients, AML in older patients is more often preceded by a hematological disorder like myelodysplasia,<sup>129</sup> is less proliferative and presents with lower white blood cell counts and lower percentages of marrow blasts.<sup>130</sup> Moreover, the spectrum of cytogenetic abnormalities changes with age and is characterized by a much higher incidence of abnormalities involving chromosomes 5 and 7, and a lower incidence of the translocations associated with favorable treatment outcomes in AML of the elderly.<sup>129-132</sup> Contributing to the difficulties of treating AML at older age might also be the observation that AML of older age more commonly expresses proteins involved in multidrug resistance.<sup>133;134</sup> Recently, we showed that AML of the elderly exhibits a distinct gene expression profile compared to AML of younger patients, including decreased expression of p16<sup>INK4a</sup>.<sup>135</sup> Based on these different clinical and biological characteristics AML of older age is increasingly considered as a separate entity.



**Figure 2 Age-specific incidence of acute myeloid leukemia**

Data include all races and both sexes and have been derived from the National Cancer Institute (Surveillance Epidemiology and End Results, 2005-2009, <http://seer.cancer.gov/>).

### *Normal hematopoietic aging in relation to malignant transformation*

It has been postulated that the phenotype of the leukemic clone(s) might be a reflection of the cell in which (epi)genetic lesions first arose. In this perspective it could be hypothesized that the distinct characteristics of AML at older age are a reflection of age-related changes in normal hematopoietic stem and progenitor cells. Moreover, it has been hypothesized that the aging process is largely the consequence of accumulated genetic damage to stem cells. Therefore, older hematopoietic stem cells might be more vulnerable to malignant transformation. In order to get insight in the impact of age on the development of AML, a thorough understanding of the aging process of the normal hematopoietic system is required. In Chapter 5 we review the effects of aging on normal hematopoietic stem and progenitor cells and speculate how the observations in murine models might be of clinical relevance.

## **Stem cell transplantation**

### *Hematopoietic stem cell transplantation*

HSCs are an appropriate source for stem cell transplantation since they can both self-renew as well as produce progeny that can differentiate into mature cells of all hematopoietic lineages. After the discovery of the regenerative effects of transplanted bone marrow in irradiated animals,<sup>4,136</sup> one of the first human bone marrow transplantations was performed between identical twins in 1959.<sup>137</sup> With the identification and typing of human leukocyte antigen (HLA), the human variant of the major histocompatibility complex,<sup>138</sup> allogeneic transplantation became feasible. In the seventies it was shown that some patients with end stage leukemia could be cured by transplanting marrow from their HLA-identical siblings after ablating the patient's marrow with total body irradiation combined with cyclophosphamide.<sup>139,140</sup> Nowadays, hematopoietic stem cell transplantation is a widely used treatment modality for a variety of hematologic malignancies and can be lifesaving. It is also increasingly used in the treatment of patients with defined congenital disorders of the hematopoietic system or severe systemic auto-immune diseases.

### *Mobilization of stem cells into the peripheral blood*

Historically, bone marrow stem cells for transplantation were obtained by repeated aspiration of the posterior iliac crests while the donor is under general or local anesthesia. This procedure is associated with a very low risk of serious complications and is therefore generally considered safe for healthy donors as well as patients.<sup>141-143</sup> Nevertheless, there has been an interest in the use of peripheral blood as a source for hematopoietic stem cells for a long time. Already in the early sixties, the presence of stem cells in the circulation was experimentally proven by transplantation experiments using whole blood or leukocytes in lethally irradiated recipients.<sup>144-146</sup> Under normal physiological conditions, undifferentiated stem cells are maintained within the bone marrow

throughout life. Only a small pool of stem cells within the bone marrow continuously produces high levels of immature and maturing myeloid and lymphoid blood cells with a limited lifespan, which are released into the circulation. However, very low levels of noncycling quiescent progenitor cells, including primitive stem cells, are also released into the peripheral blood.<sup>147,148</sup> Still, the physiological numbers of circulating stem cells are too low to collect enough stem cells for transplantation within a reasonable period of time. With the observations of increased numbers of circulating stem cells in patients presenting with chronic myeloid leukemia<sup>149,150</sup> and high numbers of circulating stem cells as a rebound phenomenon after intensive chemotherapy in patients with lymphoma or solid tumors,<sup>151</sup> peripheral blood became an available stem cell source. Since then important steps have been made with the discovery of many hematopoietic cytokines that induce the release of hematopoietic stem cells into the peripheral blood. This process of mobilization can be initiated by a wide number of molecules, including cytokines such as granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), interleukin 7 (IL 7), stem cell factor, flt-3 ligand, chemokines like IL 8 or SDF-1, and chemotherapeutic agents including cyclophosphamide.<sup>152</sup> In current clinical practice, a variety of mobilization strategies are used, including growth factors alone or in combination with chemotherapy. Of the available growth factors, the most commonly used is the bacterially synthesized recombinant G-CSF analog filgrastim, which was shown to be well-tolerated, safe and highly effective in mobilizing stem cells in most patients and healthy donors.<sup>153-156</sup> Whereas the molecular cloning and clinical development of G-CSF initially focused on the treatment of chemotherapy induced cytopenia,<sup>157-161</sup> it soon became clear that G-CSF also expanded the circulating hematopoietic stem cell pool by mobilizing CD34<sup>+</sup> hematopoietic stem and progenitor cells into the peripheral blood. More recently, the CXC chemokine receptor 4 (CXCR4) agonist plerixafor (AMD3100) was introduced as a mobilizing agent.<sup>162,163</sup> A synergistic effect of G-CSF and plerixafor on the mobilization of CD34<sup>+</sup> cells was shown.<sup>164</sup> In poor mobilizers, the combination of G-CSF and plerixafor has become the standard treatment regimen.

With the application of mobilized peripheral blood stem cells (PBSCs) a more convenient and less painful collection of stem cells for transplantation was introduced in which there is no need for anesthesia and a lower risk of bleeding, infection and nerve damage.<sup>165,166</sup> Not only are mobilized PBSCs a safe alternative for bone marrow as a source for transplantation, filgrastim-stimulated peripheral blood also has a much higher content of blood progenitor cells than bone marrow. Importantly, time to neutrophil and platelet reconstitution is uniformly reported to be shorter with PBSCs than bone marrow as stem cell source.<sup>165</sup> With the documentation of this rapid recovery together with a lower need for transfusions and antibiotics and a shorter hospital stay, an almost complete shift from bone marrow to peripheral blood as stem cell source for autologous stem cell transplantation was observed between 1992 and 1996.<sup>167</sup> However, in allogeneic transplantation the use of PBSCs increases the incidence and prolongs the treatment of chronic graft versus host disease (GVHD), since more T cells are present in the PBSC graft compared to bone marrow.<sup>168,169</sup>



Therefore, the advantages and disadvantages of peripheral blood compared to bone marrow are less clear in the allogeneic setting. Although PBSCs are used in more than 70% of all allogeneic stem cell transplantations at the present time,<sup>170</sup> concerns about the relative benefits of this source of stem cells compared to bone marrow are still legitimate. It is clear that engraftment is more rapid with PBSCs than bone marrow and that this can be associated with a reduced transplant-related mortality. Chronic GVHD can be expected to be 15-20% higher with PBSCs than bone marrow, but is associated with significant antileukemic effects, which in turn provides a major survival benefit to patients with more advanced hematologic malignancies. It is therefore suggested that patients with less-advanced hematologic malignancies might not benefit from the use of PBSCs.<sup>171;172</sup> Possibly, hematopoietic cells collected from bone marrow after donor treatment with growth factors may facilitate engraftment without increasing the risk of GVHD.<sup>173</sup> Alternatively, the development of transplantation approaches that decrease the risk of acute and extensive chronic GVHD when either stem cell source is used can be of great benefit in the future.

#### *Biology of stem cell mobilization*

Although hematopoietic stem cell mobilization has been in clinical use for many years now, the biological mechanisms underlying the egression of stem cells out of the bone marrow into the peripheral blood are not yet fully understood. The homing and retention of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow are controlled by adhesive interactions between these cells and the bone marrow micro-environment. An important mechanism in this process is the interaction between vascular cell adhesion molecule 1 (VCAM-1) which is expressed by bone marrow stromal cells, and its counter-receptor integrin  $\alpha 4\beta 1$  or very late antigen 4 (VLA-4) expressed at the surface of HSPCs.<sup>174-176</sup> Homozygous targeted deletion of the integrin  $\alpha 4$  gene results in decreased hematopoiesis in mouse embryos and decreased homing of myeloid and B lymphoid precursors in the spleen and bone marrow.<sup>174;177</sup> In adult mice, pretreatment of HSPCs with blocking anti-VLA-4 antibodies results in a profound reduction of donor HSPCs homing to the bone marrow of lethally irradiated recipients.<sup>178</sup> Moreover, administration of VLA-4 or VCAM-1 blocking antibodies induces mobilization in animal models, indicating important roles for these two molecules in this process.<sup>178;179</sup> It was also demonstrated that increased release of the proteolytic enzymes elastase and cathepsin G from murine bone marrow neutrophils during cyclophosphamide and G-CSF (and IL-8) mobilization correlated with stem cell egression. These enzymes cleave VCAM-1 from bone marrow stromal cells, preventing VLA-4 antigens expressed on the surface of hematopoietic progenitors to bind to their ligand VCAM-1 expressed by stromal cells.<sup>180;181</sup> However, the role of neutrophils and proteases in mobilization remains controversial since more recent studies demonstrate that mice lacking these proteases do not show impaired mobilization.<sup>182-184</sup> Clearly, also other mechanisms are involved. Considerable evidence strongly suggests that the dominant mechanism by which G-CSF induces HSPC mobilization is through suppression of the CXCL12/CXCR4 axis.<sup>185</sup> The chemokine CXCL12 is

also known as stromal-derived growth factor-1 (SDF-1) and has a crucial role in regulating HSPC trafficking, homing and maintenance.<sup>186-188</sup> In mice lacking CXCL12<sup>189</sup> or CXCR4<sup>190</sup> there is a failure of the migration of HSPC from the fetal liver to the bone marrow, and CXCR4<sup>-/-</sup> bone marrow chimeras exhibit constitutive mobilization.<sup>191</sup> Treatment of humans or mice with a CXCR4 antagonist results in rapid HSPC mobilization.<sup>162;192</sup>

In summary, three main processes have been implicated in G-CSF mediated mobilization, i.e. activation of proteases, inhibition of adhesion molecules and attenuation of CXCR4/CXCL12 signaling. A recent study investigated the importance of the individual mobilization processes by attempting to mobilize CXCR4<sup>-/-</sup> bone marrow chimeras with G-CSF and other agents.<sup>193</sup> These mice failed to mobilize in response to G-CSF. Interestingly, the levels of activated metalloproteinases in their bone marrow were upregulated at levels similar to wild type controls, indicating that proteolytic activity is not an independent contributor to HSPC mobilization. In contrast, these chimeric animals successfully mobilized in response to a novel small molecule antagonist to the VCAM-1/VLA-4 niche interaction termed BIO5192.<sup>194</sup> This indicates that disruption of HSPC adhesion by antagonizing VCAM-1/VLA-4 signaling is both independent of CXCR4/CXCL12 signaling and essential for the process of HSPC mobilization.

Importantly, the above described mechanisms cover only part of the story and a number of additional factors are involved in the process of mobilization. Besides the involvement of other molecular pathways and interactions, there are data suggesting the involvement of the nervous system via peripheral  $\beta$ 2-adrenergic signals<sup>195</sup> and of a circadian rhythm<sup>196;197</sup>. The relevance of these proposed mechanisms still has to be elucidated. Moreover, continued investigation of the molecular mechanisms underlying the action of G-CSF and other HSPC mobilizing agents may reveal new insights and define novel molecular targets that can be used to further develop the quality of HSPC collection for hematopoietic transplantation.

#### *Clinical applications of autologous stem cell transplantation*

More than twenty-five years ago, it was shown that high dose chemotherapy with autologous transplantation could cure some lymphomas after conventional chemotherapy had failed.<sup>198</sup> In multiple myeloma autologous stem cell transplantation was found to decrease the effects of toxicity of high dose melphalan, which was efficient in achieving remission in relapsed and refractory disease, but induced profound myelosuppression.<sup>199-201</sup> These results led to the exploration of high dose therapy with autologous stem cell support as consolidation therapy in patients with newly diagnosed multiple myeloma.<sup>202-204</sup>

Autologous transplantation is now applied more often than allogeneic transplantation.<sup>170</sup> For autologous transplantation, hematopoietic stem cells are usually frozen at temperatures below -120°C and used within a few weeks. However, when frozen, the PBSC graft is viable for years, providing the possibility to use the initially mobilized and frozen cells in case of poor regeneration or

relapsing disease. Because autologous transplantation does not induce GVHD, it can be used in older patients. Indeed, mortality is considerably lower with autologous transplantation compared to allogeneic transplantation, but the absence of graft-versus-tumor activity reduces its effectiveness in diseases sensitive to the immunological effects of donor T cells. Autologous stem cell transplantation (ASCT) has become the mainstay of treatment for multiple myeloma patients younger than 65 years of age based on improved median overall survival of approximately 12-18 months compared with chemotherapy alone.<sup>202;203;205</sup> Accordingly, multiple myeloma is the number one indication for ASCT. Nevertheless, there is continuous debate whether ASCT should be included as the standard initial therapy for all eligible patients with multiple myeloma, especially after the introduction of induction therapy with the immunomodulatory drugs (lenalidomide or thalidomide) with or without the proteasome inhibitor bortezomib in combination with steroids.<sup>206</sup> High dose therapy followed by ASCT has also become the treatment of choice for patients with relapsed aggressive non-Hodgkin lymphoma.<sup>207</sup> For patients with Hodgkin lymphoma high dose therapy followed by ASCT can be used if no complete remission can be achieved with initial therapy regimens or in case of relapse.<sup>208</sup> Recently, results of a randomized trial in acute myeloid leukemia showed an advantage for ASCT as postremission therapy in terms of relapse rate.<sup>209</sup> Although clear survival benefits could not be detected in this study, ASCT might indeed be beneficial in particular subgroups of acute myeloid leukemia patients. Finally, ASCT is increasingly used in the treatment of severe auto-immune diseases.<sup>170</sup>

## Scope of this thesis

Like the normal hematopoietic system, AML is thought to be hierarchically organized with a small subset of leukemia-initiating cells that initiate and maintain the leukemic population. These leukemia-initiating cells have been found to reside in the CD34<sup>+</sup> compartment in the majority of AML cases. Nevertheless, most gene expression profiling studies in AML have been performed with the total mononuclear cell fraction. In **Chapter 2** of this thesis we performed genome-wide gene expression studies on sorted CD34<sup>+</sup> and CD34<sup>-</sup> AML subfractions and compared these with a large group of normal CD34<sup>+</sup> bone marrow cells in order to identify AML CD34<sup>+</sup>-specific gene expression profiles. This approach was chosen to obtain information about the transcriptome of the leukemic stem cell-enriched AML fraction.

We continued on studying the CD34<sup>+</sup> and CD34<sup>-</sup> subfractions of AML, but now focused on the subgroup of NPM1-mutated AML. As described, mutations in the NPM1 gene are frequently found in AML and are of significant prognostic relevance. However, it is currently unclear how mutant NPM1 contributes to leukemic transformation and which molecular mechanisms are involved in the maintenance of the leukemia. In **Chapter 3** we examined the long-term expansion and serial replating capacities of CD34<sup>+</sup> and CD34<sup>-</sup> NPM1-mutated cells in *ex vivo* stromal co-cultures, identified a CD34<sup>+</sup> NPM1-mutated AML gene expression profile and investigated the role of MEIS1 in the long-term expansion of CD34<sup>+</sup> NPM1-mutated cells.

Mutations in the NPM1 gene lead to aberrant accumulation of nucleophosmin protein in the cytoplasm of the leukemic cells. Immunohistochemical staining of nucleophosmin on bone marrow biopsies has therefore been widely used for the detection of NPM1 mutations. Moreover, the term cytoplasmic nucleophosmin positive (NPMc<sup>+</sup>) AML is often used as a synonym for NPM1-mutated AML. In **Chapter 4** we assessed the sensitivity and specificity of immunohistochemistry compared with gold standard molecular analysis to predict NPM1 mutation status in a large cohort of AML patients from our institution. The cases that were found to have a discrepancy between the two methods were evaluated.

The relation between aging and AML is indicated by the strong increase in the incidence of myelodysplastic syndrome and AML with increasing age. Moreover, AML of older age shows distinct clinical and biological characteristics. Although major progress has been made by recent studies, data on the effects of normal aging on the human hematopoietic system are still limited. **Chapter 5** of this thesis provides a review on the effects of aging on the normal hematopoietic system with a focus on recent developments.

As is indicated in our review, aging of the hematopoietic system is especially studied in animal models. In **Chapter 6** we investigated CD34<sup>+</sup> cells derived from cord blood, young adult bone marrow and old adult bone marrow with respect to phenotype, *in vitro* function and gene expression profiles to reveal the potential effects of ontogeny and aging on human hematopoietic stem and progenitor cells. Furthermore, we considered ASCT as an experimental opportunity to study the impact of aging and stress response on human HSPCs *in vivo* and analysed the impact of age on mobilisation of HSPCs and on the short and long-term regeneration after autologous stem cell transplantation.

The setting of ASCT was also subject to our studies in the next chapter. Based on the clinical observation that ASCT induces a reduced tolerance to chemotherapy, we hypothesized that the ASCT procedure results in long-term effects on the bone marrow capacity. In **Chapter 7** CD34<sup>+</sup> bone marrow cells from patients at 6-9 months after ASCT were studied with respect to the myeloid progenitor composition, *in vitro* colony forming frequency and cell cycle status. In addition, the bone marrow compartments post-ASCT were studied *in vivo* using <sup>18</sup>F-FLT PET scans. The thymidine analogue <sup>18</sup>F-FLT can be used as a proliferation tracer, since it is phosphorylated by thymidine kinase 1 into <sup>18</sup>F-FLT-monophosphate after which it is trapped in the cell.

To follow-up on the observations in post-ASCT bone marrow, a more detailed examination of the hematopoietic stem and progenitor cell compartment post-ASCT was performed in **Chapter 8**. In this study, stem cell quiescence and stem cell frequency together with reactive oxygen species (ROS) production of CD34<sup>+</sup> cells from post-ASCT bone marrow (one year following transplantation) were studied and compared to normal bone marrow cells and mobilized peripheral blood stem cells. In addition, gene expression profiling was performed to obtain more insight in underlying molecular mechanisms.

The results of the studies outlined above are summarized in **Chapter 9**. This chapter also provides a general discussion and future perspectives.

---

**References**

1. Bryder D, Rossi DJ, Weissman IL. Hematopoietic stem cells: the paradigmatic tissue-specific stem cell. *Am.J.Pathol.* 2006;169:338-346.
2. Gordon MY, Lewis JL, Marley SB. Of mice and men...and elephants. *Blood* 2002;100:4679-4680.
3. Jacobson LO, Simmons EL, Marks EK, Eldredge JH. Recovery from radiation injury. *Science* 1951;113:510-511.
4. Lorenz E, Uphoff D, Reid TR, Shelton E. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. *J.Natl.Cancer Inst.* 1951;12:197-201.
5. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. *Radiat.Res.* 1961;14:213-222.
6. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. *Nature* 2001;414:105-111.
7. Weissman IL, Shizuru JA. The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases. *Blood* 2008;112:3543-3553.
8. Morrison SJ, Weissman IL. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. *Immunity.* 1994;1:661-673.
9. Orford KW, Scadden DT. Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. *Nat.Rev.Genet.* 2008;9:115-128.
10. Passegue E, Wagers AJ, Giuriato S, Anderson WC, Weissman IL. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. *J.Exp.Med.* 2005;202:1599-1611.
11. Pietras EM, Warr MR, Passegue E. Cell cycle regulation in hematopoietic stem cells. *J.Cell Biol.* 2011;195:709-720.
12. Challen GA, Boles NC, Chambers SM, Goodell MA. Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. *Cell Stem Cell* 2010;6:265-278.
13. Muller-Sieburg CE, Sieburg HB, Bernitz JM, Cattarossi G. Stem cell heterogeneity: implications for aging and regenerative medicine. *Blood* 2012;119:3900-3907.
14. Dykstra B, Kent D, Bowie M et al. Long-term propagation of distinct hematopoietic differentiation programs in vivo. *Cell Stem Cell* 2007;1:218-229.

15. Benz C, Copley MR, Kent DG et al. Hematopoietic stem cell subtypes expand differentially during development and display distinct lymphopoietic programs. *Cell Stem Cell* 2012;10:273-283.
16. Wilson A, Laurenti E, Oser G et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. *Cell* 2008;135:1118-1129.
17. Morrison SJ, Wandycz AM, Hemmati HD, Wright DE, Weissman IL. Identification of a lineage of multipotent hematopoietic progenitors. *Development* 1997;124:1929-1939.
18. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. *Nature* 2000;404:193-197.
19. Kondo M, Weissman IL, Akashi K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. *Cell* 1997;91:661-672.
20. Nakorn TN, Miyamoto T, Weissman IL. Characterization of mouse clonogenic megakaryocyte progenitors. *Proc.Natl.Acad.Sci.U.S.A* 2003;100:205-210.
21. Pronk CJ, Rossi DJ, Mansson R et al. Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. *Cell Stem Cell* 2007;1:428-442.
22. Adolfsson J, Mansson R, Buza-Vidas N et al. Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. *Cell* 2005;121:295-306.
23. Arinobu Y, Mizuno S, Chong Y et al. Reciprocal activation of GATA-1 and PU.1 marks initial specification of hematopoietic stem cells into myeloerythroid and myelolymphoid lineages. *Cell Stem Cell* 2007;1:416-427.
24. Lai AY, Kondo M. Asymmetrical lymphoid and myeloid lineage commitment in multipotent hematopoietic progenitors. *J.Exp.Med.* 2006;203:1867-1873.
25. Yoshida T, Ng SY, Zuniga-Pflucker JC, Georgopoulos K. Early hematopoietic lineage restrictions directed by Ikaros. *Nat.Immunol.* 2006;7:382-391.
26. Doulatov S, Notta F, Laurenti E, Dick JE. Hematopoiesis: a human perspective. *Cell Stem Cell* 2012;10:120-136.
27. Berenson RJ, Andrews RG, Bensinger WI et al. Antigen CD34+ marrow cells engraft lethally irradiated baboons. *J.Clin.Invest* 1988;81:951-955.
28. Berenson RJ, Bensinger WI, Hill R et al. Stem cell selection--clinical experience. *Prog.Clin.Biol.Res.* 1990;333:403-410.

29. Civin CI, Strauss LC, Brovall C et al. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. *J.Immunol.* 1984;133:157-165.
30. Sutherland HJ, Eaves CJ, Eaves AC, Dragowska W, Lansdorp PM. Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro. *Blood* 1989;74:1563-1570.
31. Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B. Isolation of a candidate human hematopoietic stem-cell population. *Proc.Natl.Acad.Sci.U.S.A* 1992;89:2804-2808.
32. McCune JM, Namikawa R, Kaneshima H et al. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. *Science* 1988;241:1632-1639.
33. Majeti R, Park CY, Weissman IL. Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. *Cell Stem Cell* 2007;1:635-645.
34. Bhatia M, Wang JC, Kapp U, Bonnet D, Dick JE. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. *Proc.Natl.Acad.Sci.U.S.A* 1997;94:5320-5325.
35. Bhatia M, Bonnet D, Murdoch B, Gan OI, Dick JE. A newly discovered class of human hematopoietic cells with SCID-repopulating activity. *Nat.Med.* 1998;4:1038-1045.
36. Notta F, Doulatov S, Laurenti E et al. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. *Science* 2011;333:218-221.
37. Edvardsson L, Dykes J, Olofsson T. Isolation and characterization of human myeloid progenitor populations--TpoR as discriminator between common myeloid and megakaryocyte/erythroid progenitors. *Exp.Hematol.* 2006;34:599-609.
38. Manz MG, Miyamoto T, Akashi K, Weissman IL. Prospective isolation of human clonogenic common myeloid progenitors. *Proc.Natl.Acad.Sci.U.S.A* 2002;99:11872-11877.
39. Galy A, Travis M, Cen D, Chen B. Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. *Immunity.* 1995;3:459-473.
40. Hao QL, Zhu J, Price MA et al. Identification of a novel, human multilymphoid progenitor in cord blood. *Blood* 2001;97:3683-3690.
41. Hoebeke I, De SM, Stolz F et al. T-, B- and NK-lymphoid, but not myeloid cells arise from human CD34(+)CD38(-)CD7(+) common lymphoid progenitors expressing lymphoid-specific genes. *Leukemia* 2007;21:311-319.
42. Kiel MJ, Morrison SJ. Uncertainty in the niches that maintain haematopoietic stem cells. *Nat.Rev.Immunol.* 2008;8:290-301.



43. Lympéri S, Ferraro F, Scadden DT. The HSC niche concept has turned 31. Has our knowledge matured? *Ann.N.Y.Acad.Sci.* 2010;1192:12-18.
44. Raaijmakers MH, Scadden DT. Evolving concepts on the microenvironmental niche for hematopoietic stem cells. *Curr.Opin.Hematol.* 2008;15:301-306.
45. Calvi LM, Adams GB, Weibrecht KW et al. Osteoblastic cells regulate the haematopoietic stem cell niche. *Nature* 2003;425:841-846.
46. Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. *Nature* 2012;481:457-462.
47. Kiel MJ, Yilmaz OH, Iwashita T et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. *Cell* 2005;121:1109-1121.
48. Mendez-Ferrer S, Michurina TV, Ferraro F et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. *Nature* 2010;466:829-834.
49. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. *Immunity.* 2006;25:977-988.
50. Bhatia M, Bonnet D, Wu D et al. Bone morphogenetic proteins regulate the developmental program of human hematopoietic stem cells. *J.Exp.Med.* 1999;189:1139-1148.
51. Iwasaki H, Mizuno S, Arinobu Y et al. The order of expression of transcription factors directs hierarchical specification of hematopoietic lineages. *Genes Dev.* 2006;20:3010-3021.
52. Rieger MA, Hoppe PS, Smejkal BM, Eitelhuber AC, Schroeder T. Hematopoietic cytokines can instruct lineage choice. *Science* 2009;325:217-218.
53. Rosmarin AG, Yang Z, Resendes KK. Transcriptional regulation in myelopoiesis: Hematopoietic fate choice, myeloid differentiation, and leukemogenesis. *Exp.Hematol.* 2005;33:131-143.
54. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. *N.Engl.J.Med.* 1999;341:1051-1062.
55. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. *Lancet* 2008;371:1030-1043.
56. Estey E, Dohner H. Acute myeloid leukaemia. *Lancet* 2006;368:1894-1907.
57. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. *Br.J.Haematol.* 1976;33:451-458.

58. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. *Blood* 2002;100:2292-2302.
59. Vardiman JW, Thiele J, Arber DA et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. *Blood* 2009;114:937-951.
60. Foran JM. New prognostic markers in acute myeloid leukemia: perspective from the clinic. *Hematology.Am.Soc.Hematol.Educ.Program.* 2010;2010:47-55.
61. Grimwade D, Hills RK. Independent prognostic factors for AML outcome. *Hematology.Am.Soc.Hematol.Educ.Program.* 2009;385-395.
62. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. *Blood Rev.* 2004;18:115-136.
63. Dohner H, Gaidzik VI. Impact of genetic features on treatment decisions in AML. *Hematology.Am.Soc.Hematol.Educ.Program.* 2011;2011:36-42.
64. Breems DA, Van Putten WL, De Greef GE et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. *J.Clin.Oncol.* 2008;26:4791-4797.
65. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. *Blood* 2002;100:1532-1542.
66. Kiyoi H, Naoe T, Nakano Y et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. *Blood* 1999;93:3074-3080.
67. Kottaridis PD, Gale RE, Frew ME et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. *Blood* 2001;98:1752-1759.
68. Schnittger S, Schoch C, Dugas M et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. *Blood* 2002;100:59-66.
69. Thiede C, Steudel C, Mohr B et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. *Blood* 2002;99:4326-4335.
70. Dohner H, Estey EH, Amadori S et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. *Blood* 2010;115:453-474.

71. Mead AJ, Gale RE, Hills RK et al. Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease. *Blood* 2008;112:444-445.
72. Radomska HS, Huettner CS, Zhang P et al. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. *Mol.Cell Biol.* 1998;18:4301-4314.
73. Zhang DE, Zhang P, Wang ND et al. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. *Proc.Natl.Acad.Sci.U.S.A* 1997;94:569-574.
74. Marcucci G, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. *J.Clin.Oncol.* 2011;29:475-486.
75. Taskesen E, Bullinger L, Corbacioglu A et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. *Blood* 2011;117:2469-2475.
76. Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. *Blood* 2009;113:3088-3091.
77. Dufour A, Schneider F, Metzeler KH et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. *J.Clin.Oncol.* 2010;28:570-577.
78. Abbas S, Lugthart S, Kavelaars FG et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. *Blood* 2010;116:2122-2126.
79. Marcucci G, Maharry K, Wu YZ et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. *J.Clin.Oncol.* 2010;28:2348-2355.
80. Mardis ER, Ding L, Dooling DJ et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. *N.Engl.J.Med.* 2009;361:1058-1066.
81. Xu W, Yang H, Liu Y et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. *Cancer Cell* 2011;19:17-30.
82. Green CL, Evans CM, Hills RK et al. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. *Blood* 2010;116:2779-2782.

83. Paschka P, Schlenk RF, Gaidzik VI et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. *J.Clin.Oncol.* 2010;28:3636-3643.
84. Ley TJ, Ding L, Walter MJ et al. DNMT3A mutations in acute myeloid leukemia. *N.Engl.J.Med.* 2010;363:2424-2433.
85. Yan XJ, Xu J, Gu ZH et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. *Nat.Genet.* 2011;43:309-315.
86. Thol F, Damm F, Ludeking A et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. *J.Clin.Oncol.* 2011;29:2889-2896.
87. Delhommeau F, Dupont S, Della V, V et al. Mutation in TET2 in myeloid cancers. *N.Engl.J.Med.* 2009;360:2289-2301.
88. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. *Nat.Rev.Cancer* 2006;6:493-505.
89. Yu Y, Maggi LB, Jr., Brady SN et al. Nucleophosmin is essential for ribosomal protein L5 nuclear export. *Mol.Cell Biol.* 2006;26:3798-3809.
90. Kuo ML, den BW, Bertwistle D, Roussel MF, Sherr CJ. N-terminal polyubiquitination and degradation of the Arf tumor suppressor. *Genes Dev.* 2004;18:1862-1874.
91. Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG. Nucleophosmin regulates the stability and transcriptional activity of p53. *Nat.Cell Biol.* 2002;4:529-533.
92. Colombo E, Alcalay M, Pelicci PG. Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases. *Oncogene* 2011;30:2595-2609.
93. Wang W, Budhu A, Forgues M, Wang XW. Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. *Nat.Cell Biol.* 2005;7:823-830.
94. Okuda M. The role of nucleophosmin in centrosome duplication. *Oncogene* 2002;21:6170-6174.
95. Grisendi S, Bernardi R, Rossi M et al. Role of nucleophosmin in embryonic development and tumorigenesis. *Nature* 2005;437:147-153.
96. Falini B, Mecucci C, Tiacci E et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. *N.Engl.J.Med.* 2005;352:254-266.
97. Falini B, Nicoletti I, Bolli N et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. *Haematologica* 2007;92:519-532.

98. Schnittger S, Schoch C, Kern W et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. *Blood* 2005;106:3733-3739.
99. Thiede C, Koch S, Creutzig E et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). *Blood* 2006;107:4011-4020.
100. Verhaak RG, Goudswaard CS, van Putten W et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. *Blood* 2005;106:3747-3754.
101. Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. *Blood* 2007;109:874-885.
102. Rau R, Brown P. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. *Hematol.Oncol.* 2009;27:171-181.
103. Albiero E, Madeo D, Bolli N et al. Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation. *Leukemia* 2007;21:1099-1103.
104. Mariano AR, Colombo E, Luzi L et al. Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal. *Oncogene* 2006;25:4376-4380.
105. Pitiot AS, Santamaria I, Garcia-Suarez O et al. A new type of NPM1 gene mutation in AML leading to a C-terminal truncated protein. *Leukemia* 2007;21:1564-1566.
106. Falini B, Bolli N, Liso A et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. *Leukemia* 2009;23:1731-1743.
107. Falini B, Martelli MP, Bolli N et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. *Blood* 2006;108:1999-2005.
108. Falini B, Martelli MP, Pileri SA, Mecucci C. Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help. *Haematologica* 2010;95:529-534.
109. Luo J, Qi C, Xu W et al. Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype. *Am.J.Clin.Pathol.* 2010;133:34-40.

110. Konoplev S, Huang X, Drabkin HA et al. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis. *Cancer* 2009;115:4737-4744.
111. Pasqualucci L, Liso A, Martelli MP et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification. *Blood* 2006;108:4146-4155.
112. Suzuki T, Kiyoi H, Ozeki K et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. *Blood* 2005;106:2854-2861.
113. Alcalay M, Tiacci E, Bergomas R et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. *Blood* 2005;106:899-902.
114. Garzon R, Garofalo M, Martelli MP et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. *Proc.Natl.Acad.Sci.U.S.A* 2008;105:3945-3950.
115. Dohner K, Schlenk RF, Habdank M et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. *Blood* 2005;106:3740-3746.
116. Schlenk RF, Dohner K, Krauter J et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. *N.Engl.J.Med.* 2008;358:1909-1918.
117. Becker H, Marcucci G, Maharry K et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. *J.Clin.Oncol.* 2010;28:596-604.
118. Schlenk RF, Dohner K, Kneba M et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. *Haematologica* 2009;94:54-60.
119. Buchner T, Berdel WE, Haferlach C et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. *J.Clin.Oncol.* 2009;27:61-69.
120. Rollig C, Thiede C, Gramatzki M et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. *Blood* 2010;116:971-978.
121. Fernandez HF, Sun Z, Yao X et al. Anthracycline dose intensification in acute myeloid leukemia. *N.Engl.J.Med.* 2009;361:1249-1259.

122. Mandelli F, Vignetti M, Suci S et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. *J.Clin.Oncol.* 2009;27:5397-5403.
123. Dick JE. Stem cell concepts renew cancer research. *Blood* 2008;112:4793-4807.
124. McCulloch EA, Till JE. Blast cells in acute myeloblastic leukemia: a model. *Blood Cells* 1981;7:63-77.
125. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nat.Med.* 1997;3:730-737.
126. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. *Nature* 1994;367:645-648.
127. Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. *Cancer* 2006;107:2099-2107.
128. Juliusson G, Antunovic P, Derolf A et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. *Blood* 2009;113:4179-4187.
129. Grimwade D, Walker H, Harrison G et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. *Blood* 2001;98:1312-1320.
130. Appelbaum FR, Gundacker H, Head DR et al. Age and acute myeloid leukemia. *Blood* 2006;107:3481-3485.
131. Moorman AV, Roman E, Willett EV et al. Karyotype and age in acute myeloid leukemia. Are they linked? *Cancer Genet.Cytogenet.* 2001;126:155-161.
132. Schoch C, Kern W, Krawitz P et al. Dependence of age-specific incidence of acute myeloid leukemia on karyotype. *Blood* 2001;98:3500.
133. Leith CP, Kopecky KJ, Godwin J et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. *Blood* 1997;89:3323-3329.
134. Leith CP, Kopecky KJ, Chen IM et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. *Blood* 1999;94:1086-1099.

135. de Jonge HJ, de Bont ES, Valk PJ et al. AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance. *Blood* 2009;114:2869-2877.
136. Mannick JA, Lochte HL, Jr., Ashley CA, Thomas ED, Ferrebee JW. Autografts of bone marrow in dogs after lethal total-body radiation. *Blood* 1960;15:255-266.
137. Thomas ED, Lochte HL, Jr., Cannon JH, Sahler OD, Ferrebee JW. Supralethal whole body irradiation and isologous marrow transplantation in man. *J.Clin.Invest* 1959;38:1709-1716.
138. Klein J, Sato A. The HLA system. First of two parts. *N.Engl.J.Med.* 2000;343:702-709.
139. Thomas ED, Buckner CD, Banaji M et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. *Blood* 1977;49:511-533.
140. Thomas ED, Buckner CD, Clift RA et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. *N.Engl.J.Med.* 1979;301:597-599.
141. Bortin MM, Buckner CD. Major complications of marrow harvesting for transplantation. *Exp.Hematol.* 1983;11:916-921.
142. Buckner CD, Clift RA, Sanders JE et al. Marrow harvesting from normal donors. *Blood* 1984;64:630-634.
143. Jin NR, Hill RS, Petersen FB et al. Marrow harvesting for autologous marrow transplantation. *Exp.Hematol.* 1985;13:879-884.
144. Cronkite EP. Response to "Mobilization of peripheral blood 'stem' cells: where there is smoke, is there fire?" Yes, there have been many fires, leaving cold coals. *Exp.Hematol.* 1997;25:185-186.
145. Goodman JW, Hodgson GS. Evidence for stem cells in the peripheral blood of mice. *Blood* 1962;19:702-714.
146. Papayannopoulou T, Scadden DT. Stem-cell ecology and stem cells in motion. *Blood* 2008;111:3923-3930.
147. Morrison SJ, Uchida N, Weissman IL. The biology of hematopoietic stem cells. *Annu.Rev.Cell Dev.Biol.* 1995;11:35-71.
148. Wright DE, Wagers AJ, Gulati AP, Johnson FL, Weissman IL. Physiological migration of hematopoietic stem and progenitor cells. *Science* 2001;294:1933-1936.
149. Goldman JM, Catovsky D, Hows J, Spiers AS, Galton DA. Cryopreserved peripheral blood cells functioning as autografts in patients with chronic granulocytic leukaemia in transformation. *Br.Med.J.* 1979;1:1310-1313.



150. Haines ME, Goldman JM, Worsley AM et al. Chemotherapy and autografting for chronic granulocytic leukaemia in transformation: probable prolongation of survival for some patients. *Br.J.Haematol.* 1984;58:711-721.
151. Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. *Blood* 1976;47:1031-1039.
152. Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. *Exp.Hematol.* 2002;30:973-981.
153. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. *Lancet* 1996;347:353-357.
154. Anderlini P, Rizzo JD, Nugent ML et al. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. *Bone Marrow Transplant.* 2001;27:689-692.
155. McCullough J, Kahn J, Adamson J et al. Hematopoietic growth factors--use in normal blood and stem cell donors: clinical and ethical issues. *Transfusion* 2008;48:2008-2025.
156. Pulsipher MA, Chitphakdithai P, Miller JP et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. *Blood* 2009;113:3604-3611.
157. Bronchud MH, Scarffe JH, Thatcher N et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. *Br.J.Cancer* 1987;56:809-813.
158. Gabrilove JL, Jakubowski A, Scher H et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. *N.Engl.J.Med.* 1988;318:1414-1422.
159. Welte K, Platzer E, Lu L et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. *Proc.Natl.Acad.Sci.U.S.A* 1985;82:1526-1530.
160. Welte K, Bonilla MA, Gillio AP et al. Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. *J.Exp.Med.* 1987;165:941-948.
161. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. *Blood* 1996;88:1907-1929.

162. Liles WC, Broxmeyer HE, Rodger E et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. *Blood* 2003;102:2728-2730.
163. Pusic I, DiPersio JF. Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. *Curr.Opin.Hematol.* 2010;17:319-326.
164. Liles WC, Rodger E, Broxmeyer HE et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. *Transfusion* 2005;45:295-300.
165. Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? *Blood* 2001;98:2900-2908.
166. Korbling M, Champlin R. Peripheral blood progenitor cell transplantation: a replacement for marrow auto- or allografts. *Stem Cells* 1996;14:185-195.
167. Gratwohl A, Baldomero H, Schmid O et al. Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003. *Bone Marrow Transplant.* 2005;36:575-590.
168. Cutler C, Giri S, Jeyapalan S et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. *J.Clin.Oncol.* 2001;19:3685-3691.
169. Stewart BL, Storer B, Storek J et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. *Blood* 2004;104:3501-3506.
170. Baldomero H, Gratwohl M, Gratwohl A et al. The EBMT activity survey 2009: trends over the past 5 years. *Bone Marrow Transplant.* 2011;46:485-501.
171. Bensinger WI. Allogeneic transplantation: peripheral blood vs. bone marrow. *Curr.Opin.Oncol.* 2012;24:191-196.
172. Anasetti C, Logan BR, Lee SJ et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. *N.Engl.J.Med.* 2012;367:1487-1496.
173. Morton J, Hutchins C, Durrant S. Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. *Blood* 2001;98:3186-3191.
174. Arroyo AG, Taverna D, Whittaker CA et al. In vivo roles of integrins during leukocyte development and traffic: insights from the analysis of mice chimeric for alpha 5, alpha v, and alpha 4 integrins. *J.Immunol.* 2000;165:4667-4675.

175. Frenette PS, Subbarao S, Mazo IB, von Andrian UH, Wagner DD. Endothelial selectins and vascular cell adhesion molecule-1 promote hematopoietic progenitor homing to bone marrow. *Proc.Natl.Acad.Sci.U.S.A* 1998;95:14423-14428.
176. Verfaillie CM. Adhesion receptors as regulators of the hematopoietic process. *Blood* 1998;92:2609-2612.
177. Arroyo AG, Yang JT, Rayburn H, Hynes RO. Alpha4 integrins regulate the proliferation/differentiation balance of multilineage hematopoietic progenitors in vivo. *Immunity*. 1999;11:555-566.
178. Vermeulen M, Le PF, Gagnerault MC et al. Role of adhesion molecules in the homing and mobilization of murine hematopoietic stem and progenitor cells. *Blood* 1998;92:894-900.
179. Papayannopoulou T, Nakamoto B. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. *Proc.Natl.Acad.Sci.U.S.A* 1993;90:9374-9378.
180. Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. *Blood* 2001;98:1289-1297.
181. Levesque JP, Hendy J, Takamatsu Y et al. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. *Exp.Hematol*. 2002;30:440-449.
182. Christopher MJ, Rao M, Liu F, Woloszynek JR, Link DC. Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. *J.Exp.Med*. 2011;208:251-260.
183. Levesque JP, Liu F, Simmons PJ et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. *Blood* 2004;104:65-72.
184. Robinson SN, Pisarev VM, Chavez JM, Singh RK, Talmadge JE. Use of matrix metalloproteinase (MMP)-9 knockout mice demonstrates that MMP-9 activity is not absolutely required for G-CSF or Flt-3 ligand-induced hematopoietic progenitor cell mobilization or engraftment. *Stem Cells* 2003;21:417-427.
185. Petit I, Szyper-Kravitz M, Nagler A et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. *Nat.Immunol*. 2002;3:687-694.
186. Cashman J, Clark-Lewis I, Eaves A, Eaves C. Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. *Blood* 2002;99:792-799.
187. Kawabata K, Ujikawa M, Egawa T et al. A cell-autonomous requirement for CXCR4 in long-term lymphoid and myeloid reconstitution. *Proc.Natl.Acad.Sci.U.S.A* 1999;96:5663-5667.

188. Peled A, Petit I, Kollet O et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. *Science* 1999;283:845-848.
189. Nagasawa T, Hirota S, Tachibana K et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. *Nature* 1996;382:635-638.
190. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. *Nature* 1998;393:595-599.
191. Ma Q, Jones D, Springer TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. *Immunity*. 1999;10:463-471.
192. Broxmeyer HE, Orschell CM, Clapp DW et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. *J.Exp.Med.* 2005;201:1307-1318.
193. Christopher MJ, Liu F, Hilton MJ, Long F, Link DC. Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. *Blood* 2009;114:1331-1339.
194. Ramirez P, Rettig MP, Uy GL et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. *Blood* 2009;114:1340-1343.
195. Katayama Y, Battista M, Kao WM et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. *Cell* 2006;124:407-421.
196. Lucas D, Battista M, Shi PA, Isola L, Frenette PS. Mobilized hematopoietic stem cell yield depends on species-specific circadian timing. *Cell Stem Cell* 2008;3:364-366.
197. Mendez-Ferrer S, Lucas D, Battista M, Frenette PS. Haematopoietic stem cell release is regulated by circadian oscillations. *Nature* 2008;452:442-447.
198. Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. *N.Engl.J.Med.* 1987;316:1493-1498.
199. Alexanian R, Dimopoulos MA, Hester J, Delasalle K, Champlin R. Early myeloablative therapy for multiple myeloma. *Blood* 1994;84:4278-4282.
200. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. *Blood* 1986;67:1298-1301.
201. Barlogie B, Alexanian R, Dicke KA et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. *Blood* 1987;70:869-872.

202. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. *N.Engl.J.Med.* 1996;335:91-97.
203. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. *N.Engl.J.Med.* 2003;348:1875-1883.
204. Femand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. *Blood* 1998;92:3131-3136.
205. Rajkumar SV. Treatment of multiple myeloma. *Nat.Rev.Clin.Oncol.* 2011;8:479-491.
206. Moreau P, Rajkumar SV. "Should all eligible patients with multiple myeloma receive autologous stem-cell transplant as part of initial treatment?". *Leuk.Res.* 2012;36:677-681.
207. Nademanee A. Transplantation for non-Hodgkin lymphoma. *Expert.Rev.Hematol.* 2009;2:425-442.
208. Copeland A, Younes A. Current treatment strategies in Hodgkin lymphomas. *Curr.Opin.Oncol.* 2012;24:466-474.
209. Vellenga E, van Putten W, Ossenkoppele GJ et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. *Blood* 2011;118:6037-6042.



